{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:24:27Z","timestamp":1787289867636,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01149-w","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:40:20Z","timestamp":1787287220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful cabazitaxel desensitization after severe taxane hypersensitivity reactions: a brief report"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6865-844X","authenticated-orcid":false,"given":"Stephanie","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2892-9184","authenticated-orcid":false,"given":"Bilal","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallie","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"1149_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4168\/aair.2024.16.2.142","volume":"16","author":"MS Bayrak Durmaz","year":"2024","unstructured":"Bayrak Durmaz MS, Unutmaz DG, Demir M, Goksel O, Dursun AB, Bavbek S. Hypersensitivity reactions to taxanes: a multicenter study for outcomes and safety of rapid drug desensitization. Allergy Asthma Immunol Res. 2024;16:142\u201353.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1149_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","volume":"96","author":"AM Feldweg","year":"2005","unstructured":"Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96:824\u20139.","journal-title":"Gynecol Oncol"},{"key":"1149_CR3","first-page":"A240","volume":"23","author":"JC Garciadeparedes-esteban","year":"2016","unstructured":"Garciadeparedes-esteban JC, Fenix-Caballero S, Mart\u00ednez-D\u00edaz C, Fern\u00e1ndez-Anguita MJ, Camean-Castillo M, Gil-Sierra MD, et al. Desensitisation protocol for cabazitaxel: a case report. Eur J Hospital Pharm. 2016;23:A240\u2013A1.","journal-title":"Eur J Hospital Pharm"},{"key":"1149_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"1149_CR5","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506\u201318.","journal-title":"N Engl J Med"},{"key":"1149_CR6","first-page":"658","volume":"14","author":"X Yin","year":"2019","unstructured":"Yin X, Luo L, Li W, Yang J, Zhu C, Jiang M, et al. A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity. Asian J Pharm Sci. 2019;14:658\u201367.","journal-title":"Asian J Pharm Sci"},{"key":"1149_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1385\/CRIAI:24:3:253","volume":"24","author":"GM Shepherd","year":"2003","unstructured":"Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:253\u201362.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1149_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","volume":"7","author":"R Madrigal-Burgaleta","year":"2019","unstructured":"Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, \u00c1lvarez-Cuesta E. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pr. 2019;7:618\u201332.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"1149_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","volume":"122","author":"MC Castells","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574\u201380.","journal-title":"J Allergy Clin Immunol"},{"key":"1149_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019;20:1432\u201343.","journal-title":"Lancet Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01149-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01149-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01149-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:40:32Z","timestamp":1787287232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01149-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":10,"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01149-w","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS, BA, and KW declare no conflicts of interest. AA declares research support (to Duke) from the NIH\/NCI, PCF, DOD, Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Pathos, Amgen, Novartis, Fibrogen and consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Exelixis, Novartis, Medscape, Telix, Duality Bio, MedIQ, IDEOlogy, Sumitomo, and Precede Bio.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}